Order Article Reprints

Deshet-Unger N, Horn G, Rawet-Slobodkin M, Waks T, Laskov I, Michaan N, Raz Y, Bar V, Zundelevich A, Aharon S, et al. Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines. 2022; 10(9):2216. https://doi.org/10.3390/biomedicines10092216

Deshet-Unger, Naamit, Galit Horn, Moran Rawet-Slobodkin, Tova Waks, Ido Laskov, Nadav Michaan, Yael Raz, Vered Bar, Adi Zundelevich, Sara Aharon, and et al. 2022. "Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer" Biomedicines 10, no. 9: 2216. https://doi.org/10.3390/biomedicines10092216

Deshet-Unger, N., Horn, G., Rawet-Slobodkin, M., Waks, T., Laskov, I., Michaan, N., Raz, Y., Bar, V., Zundelevich, A., Aharon, S., Turovsky, L., Mallel, G., Salpeter, S., Neev, G., Hollander, K. S., Katz, B. -Z., Grisaru, D., & Globerson Levin, A. (2022). Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines, 10(9), 2216. https://doi.org/10.3390/biomedicines10092216